AVROBIO, Inc. (NASDAQ:AVRO) Short Interest Up 14.6% in March

AVROBIO, Inc. (NASDAQ:AVRO) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 143,200 shares, a growth of 14.6% from the March 15th total of 125,000 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 299,800 shares, the short-interest ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, Mizuho cut AVROBIO from a “buy” rating to a “neutral” rating and lowered their target price for the company from $5.00 to $2.00 in a research report on Monday, December 18th.

AVROBIO Price Performance

Shares of AVROBIO stock traded down $0.01 on Tuesday, hitting $1.25. The company had a trading volume of 98,740 shares, compared to its average volume of 284,023. The business has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.37. AVROBIO has a 52 week low of $0.57 and a 52 week high of $1.70. The company has a market cap of $56.08 million, a PE ratio of -12.45 and a beta of 1.22.

Hedge Funds Weigh In On AVROBIO

Hedge funds have recently made changes to their positions in the business. Boothbay Fund Management LLC purchased a new stake in shares of AVROBIO during the second quarter valued at $26,000. BNP Paribas Arbitrage SA lifted its stake in AVROBIO by 931.4% during the second quarter. BNP Paribas Arbitrage SA now owns 32,108 shares of the company’s stock valued at $30,000 after buying an additional 28,995 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of AVROBIO in the third quarter worth about $33,000. Mirabella Financial Services LLP purchased a new position in shares of AVROBIO in the first quarter worth approximately $42,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of AVROBIO during the fourth quarter valued at approximately $68,000. Institutional investors and hedge funds own 62.63% of the company’s stock.

AVROBIO Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.